South Korea · Delayed Price · Currency is KRW GL Pharm Tech Statistics
Total Valuation
GL Pharm Tech has a market cap or net worth of KRW 81.04 billion. The enterprise value is 96.09 billion.
| Market Cap | 81.04B |
| Enterprise Value | 96.09B |
Important Dates
The next estimated earnings date is Wednesday, March 18, 2026.
| Earnings Date | Mar 18, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
GL Pharm Tech has 77.55 million shares outstanding. The number of shares has increased by 8.41% in one year.
| Current Share Class | 77.55M |
| Shares Outstanding | 77.55M |
| Shares Change (YoY) | +8.41% |
| Shares Change (QoQ) | +4.80% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 51.87M |
Valuation Ratios
The trailing PE ratio is 261.11.
| PE Ratio | 261.11 |
| Forward PE | n/a |
| PS Ratio | 2.36 |
| PB Ratio | 4.05 |
| P/TBV Ratio | 4.36 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 54.99, with an EV/FCF ratio of -15.45.
| EV / Earnings | 312.66 |
| EV / Sales | 2.80 |
| EV / EBITDA | 54.99 |
| EV / EBIT | 156.29 |
| EV / FCF | -15.45 |
Financial Position
The company has a current ratio of 1.26, with a Debt / Equity ratio of 0.87.
| Current Ratio | 1.26 |
| Quick Ratio | 0.55 |
| Debt / Equity | 0.87 |
| Debt / EBITDA | 10.04 |
| Debt / FCF | -2.80 |
| Interest Coverage | 1.04 |
Financial Efficiency
Return on equity (ROE) is 1.55% and return on invested capital (ROIC) is 1.75%.
| Return on Equity (ROE) | 1.55% |
| Return on Assets (ROA) | 0.87% |
| Return on Invested Capital (ROIC) | 1.75% |
| Return on Capital Employed (ROCE) | 2.01% |
| Weighted Average Cost of Capital (WACC) | 6.93% |
| Revenue Per Employee | 1.04B |
| Profits Per Employee | 9.31M |
| Employee Count | 33 |
| Asset Turnover | 0.79 |
| Inventory Turnover | 2.05 |
Taxes
In the past 12 months, GL Pharm Tech has paid 5.43 million in taxes.
| Income Tax | 5.43M |
| Effective Tax Rate | 1.74% |
Stock Price Statistics
The stock price has increased by +6.74% in the last 52 weeks. The beta is 0.63, so GL Pharm Tech's price volatility has been lower than the market average.
| Beta (5Y) | 0.63 |
| 52-Week Price Change | +6.74% |
| 50-Day Moving Average | 1,155.58 |
| 200-Day Moving Average | 1,183.78 |
| Relative Strength Index (RSI) | 38.37 |
| Average Volume (20 Days) | 367,812 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, GL Pharm Tech had revenue of KRW 34.30 billion and earned 307.33 million in profits. Earnings per share was 4.00.
| Revenue | 34.30B |
| Gross Profit | 14.93B |
| Operating Income | 605.35M |
| Pretax Income | 312.76M |
| Net Income | 307.33M |
| EBITDA | 1.74B |
| EBIT | 605.35M |
| Earnings Per Share (EPS) | 4.00 |
Balance Sheet
The company has 2.39 billion in cash and 17.44 billion in debt, with a net cash position of -15.05 billion or -194.09 per share.
| Cash & Cash Equivalents | 2.39B |
| Total Debt | 17.44B |
| Net Cash | -15.05B |
| Net Cash Per Share | -194.09 |
| Equity (Book Value) | 20.01B |
| Book Value Per Share | 259.14 |
| Working Capital | 4.19B |
Cash Flow
In the last 12 months, operating cash flow was -3.60 billion and capital expenditures -2.62 billion, giving a free cash flow of -6.22 billion.
| Operating Cash Flow | -3.60B |
| Capital Expenditures | -2.62B |
| Free Cash Flow | -6.22B |
| FCF Per Share | -80.19 |
Margins
Gross margin is 43.53%, with operating and profit margins of 1.76% and 0.90%.
| Gross Margin | 43.53% |
| Operating Margin | 1.76% |
| Pretax Margin | 0.91% |
| Profit Margin | 0.90% |
| EBITDA Margin | 5.07% |
| EBIT Margin | 1.76% |
| FCF Margin | n/a |
Dividends & Yields
GL Pharm Tech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.41% |
| Shareholder Yield | -8.41% |
| Earnings Yield | 0.38% |
| FCF Yield | -7.67% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
GL Pharm Tech has an Altman Z-Score of 2.16 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.16 |
| Piotroski F-Score | 4 |